53 related articles for article (PubMed ID: 9020492)
1. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
Massard C; Kramar A; Beyer J; Hartmann JT; Lorch A; Pico JL; Rosti G; Droz JP; Fizazi K
Ann Oncol; 2013 Feb; 24(2):322-328. PubMed ID: 23104726
[TBL] [Abstract][Full Text] [Related]
2. Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors.
Arrieta O; Michel Ortega RM; Angeles-Sánchez J; Villarreal-Garza C; Avilés-Salas A; Chanona-Vilchis JG; Aréchaga-Ocampo E; Luévano-González A; Jiménez MA; Aguilar JL
J Exp Clin Cancer Res; 2009 Aug; 28(1):120. PubMed ID: 19709439
[TBL] [Abstract][Full Text] [Related]
3. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration.
Steyerberg EW; Pencina MJ; Lingsma HF; Kattan MW; Vickers AJ; Van Calster B
Eur J Clin Invest; 2012 Feb; 42(2):216-28. PubMed ID: 21726217
[TBL] [Abstract][Full Text] [Related]
4. Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors.
Kawaguchi T; Kumabe T; Kanamori M; Saito R; Yamashita Y; Sonoda Y; Watanabe M; Tominaga T
J Neurooncol; 2011 Sep; 104(3):779-87. PubMed ID: 21359564
[TBL] [Abstract][Full Text] [Related]
5. Canadian consensus guidelines for the management of testicular germ cell cancer.
Wood L; Kollmannsberger C; Jewett M; Chung P; Hotte S; O'Malley M; Sweet J; Anson-Cartwright L; Winquist E; North S; Tyldesley S; Sturgeon J; Gospodarowicz M; Segal R; Cheng T; Venner P; Moore M; Albers P; Huddart R; Nichols C; Warde P
Can Urol Assoc J; 2010 Apr; 4(2):e19-38. PubMed ID: 20368885
[No Abstract] [Full Text] [Related]
6. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
Bokemeyer C; Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Claussen CD; Bares R; Kanz L
Br J Cancer; 2002 Feb; 86(4):506-11. PubMed ID: 11870528
[TBL] [Abstract][Full Text] [Related]
7. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
Christensen TB; Engbaek F; Marqversen J; Nielsen SI; Kamby C; von der Maase H
Br J Cancer; 1999 Jul; 80(10):1577-81. PubMed ID: 10408402
[TBL] [Abstract][Full Text] [Related]
8. [Primary intracranial malignant germ cell tumor associated with abnormal high value of alpha-fetoprotein and human chorionic gonadotropin].
Nishiyama K; Nishida K; Kusaka K; Morizumi H
No Shinkei Geka; 1987 Dec; 15(12):1337-42. PubMed ID: 2452372
[TBL] [Abstract][Full Text] [Related]
9. [The role of tumor markers in the treatment of germ cell tumor].
Niwakawa M; Tobisu K
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
[TBL] [Abstract][Full Text] [Related]
10. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
12. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
[TBL] [Abstract][Full Text] [Related]
14. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
Price P; Hogan SJ; Bliss JM; Horwich A
Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
[TBL] [Abstract][Full Text] [Related]
15. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
